Inventiva SA
(NASDAQ : IVA)

( )
IVA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -1.85%731.862.6%$754.70m
AMGNAmgen, Inc. -1.23%230.941.4%$608.51m
MRNAModerna, Inc. -0.37%125.150.0%$589.94m
BIIBBiogen, Inc. 0.22%262.261.8%$580.04m
GILDGilead Sciences, Inc. -0.76%64.951.0%$550.05m
VRTXVertex Pharmaceuticals, Inc. -1.12%298.631.9%$429.92m
ILMNIllumina, Inc. -2.65%212.723.2%$410.84m
SNSSSunesis Pharmaceuticals, Inc. -1.47%4.020.7%$281.01m
SAVACassava Sciences, Inc. 3.37%42.350.0%$189.68m
BNTXBioNTech SE 0.25%137.530.0%$109.40m
TECHBio-Techne Corp. 0.17%309.084.5%$100.77m
BMRNBioMarin Pharmaceutical, Inc. 2.18%91.484.2%$95.92m
NVAXNovavax, Inc. -3.32%18.0875.6%$79.49m
PRTAProthena Corp. Plc 0.79%58.5713.8%$79.21m
SNTISenti Biosciences, Inc. 23.49%6.520.0%$78.99m

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.